Your browser doesn't support javascript.
loading
Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.
Meagher, Nicola S; Gorringe, Kylie L; Wakefield, Matthew; Bolithon, Adelyn; Pang, Chi Nam Ignatius; Chiu, Derek S; Anglesio, Michael S; Mallitt, Kylie-Ann; Doherty, Jennifer A; Harris, Holly R; Schildkraut, Joellen M; Berchuck, Andrew; Cushing-Haugen, Kara L; Chezar, Ksenia; Chou, Angela; Tan, Adeline; Alsop, Jennifer; Barlow, Ellen; Beckmann, Matthias W; Boros, Jessica; Bowtell, David D L; Brand, Alison H; Brenton, James D; Campbell, Ian; Cheasley, Dane; Cohen, Joshua; Cybulski, Cezary; Elishaev, Esther; Erber, Ramona; Farrell, Rhonda; Fischer, Anna; Fu, Zhuxuan; Gilks, Blake; Gill, Anthony J; Gourley, Charlie; Grube, Marcel; Harnett, Paul R; Hartmann, Arndt; Hettiaratchi, Anusha; Høgdall, Claus K; Huzarski, Tomasz; Jakubowska, Anna; Jimenez-Linan, Mercedes; Kennedy, Catherine J; Kim, Byoung-Gie; Kim, Jae-Weon; Kim, Jae-Hoon; Klett, Kayla; Koziak, Jennifer M; Lai, Tiffany.
Afiliação
  • Meagher NS; School of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
  • Gorringe KL; Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
  • Wakefield M; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Bolithon A; Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, Victoria, Australia.
  • Pang CNI; The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
  • Chiu DS; Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, Australia.
  • Anglesio MS; Department of Obstetrics and Gynaecology, The University of Melbourne, Melbourne, Victoria, Australia.
  • Mallitt KA; School of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
  • Doherty JA; Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
  • Harris HR; School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, New South Wales, Australia.
  • Schildkraut JM; Bioinformatics Unit, Children's Medical Research Institute, Westmead, Sydney, Australia.
  • Berchuck A; British Columbia's Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
  • Cushing-Haugen KL; British Columbia's Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
  • Chezar K; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
  • Chou A; School of Clinical Medicine, Faculty of Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
  • Tan A; Centre for Big Data Research in Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.
  • Alsop J; Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah.
  • Barlow E; Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Beckmann MW; Department of Epidemiology, University of Washington, Seattle, Washington.
  • Boros J; Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
  • Bowtell DDL; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina.
  • Brand AH; Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
  • Brenton JD; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • Campbell I; Department of Anatomical Pathology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  • Cheasley D; The University of Sydney, Sydney, New South Wales, Australia.
  • Cohen J; Division of Obstetrics and Gynaecology, Medical School, University of Western Australia, Crawley, Western Australia, Australia.
  • Cybulski C; Western Women's Pathology, Western Diagnostic Pathology, Wembley, Western Australia, Australia.
  • Elishaev E; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
  • Erber R; Gynaecological Cancer Centre, Royal Hospital for Women, Sydney, New South Wales, Australia.
  • Farrell R; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
  • Fischer A; The University of Sydney, Sydney, New South Wales, Australia.
  • Fu Z; Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
  • Gilks B; Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Gill AJ; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Grube M; The University of Sydney, Sydney, New South Wales, Australia.
  • Harnett PR; Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Hartmann A; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
  • Hettiaratchi A; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Høgdall CK; Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, Victoria, Australia.
  • Huzarski T; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Jakubowska A; Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, Victoria, Australia.
  • Jimenez-Linan M; David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California.
  • Kennedy CJ; Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
  • Kim BG; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • Kim JW; Institute of Pathology, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander Universität Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany.
  • Kim JH; The University of Sydney, Sydney, New South Wales, Australia.
  • Klett K; Prince of Wales Private Hospital, Randwick, New South Wales, Australia.
  • Koziak JM; Institute of Pathology and Neuropathology, Tübingen University Hospital, Tübingen, Germany.
  • Lai T; Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania.
Clin Cancer Res ; 28(24): 5383-5395, 2022 12 15.
Article em En | MEDLINE | ID: mdl-36222710
PURPOSE: Advanced-stage mucinous ovarian carcinoma (MOC) has poor chemotherapy response and prognosis and lacks biomarkers to aid stage I adjuvant treatment. Differentiating primary MOC from gastrointestinal (GI) metastases to the ovary is also challenging due to phenotypic similarities. Clinicopathologic and gene-expression data were analyzed to identify prognostic and diagnostic features. EXPERIMENTAL DESIGN: Discovery analyses selected 19 genes with prognostic/diagnostic potential. Validation was performed through the Ovarian Tumor Tissue Analysis consortium and GI cancer biobanks comprising 604 patients with MOC (n = 333), mucinous borderline ovarian tumors (MBOT, n = 151), and upper GI (n = 65) and lower GI tumors (n = 55). RESULTS: Infiltrative pattern of invasion was associated with decreased overall survival (OS) within 2 years from diagnosis, compared with expansile pattern in stage I MOC [hazard ratio (HR), 2.77; 95% confidence interval (CI), 1.04-7.41, P = 0.042]. Increased expression of THBS2 and TAGLN was associated with shorter OS in MOC patients (HR, 1.25; 95% CI, 1.04-1.51, P = 0.016) and (HR, 1.21; 95% CI, 1.01-1.45, P = 0.043), respectively. ERBB2 (HER2) amplification or high mRNA expression was evident in 64 of 243 (26%) of MOCs, but only 8 of 243 (3%) were also infiltrative (4/39, 10%) or stage III/IV (4/31, 13%). CONCLUSIONS: An infiltrative growth pattern infers poor prognosis within 2 years from diagnosis and may help select stage I patients for adjuvant therapy. High expression of THBS2 and TAGLN in MOC confers an adverse prognosis and is upregulated in the infiltrative subtype, which warrants further investigation. Anti-HER2 therapy should be investigated in a subset of patients. MOC samples clustered with upper GI, yet markers to differentiate these entities remain elusive, suggesting similar underlying biology and shared treatment strategies.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Adenocarcinoma Mucinoso / Neoplasias Gastrointestinais Tipo de estudo: Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Adenocarcinoma Mucinoso / Neoplasias Gastrointestinais Tipo de estudo: Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article